Investigational drug · Phase 3
MIL62
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Systemic Lupus Erythematosus, Neuromyelitis Optica Spectrum Disorder, Primary Membranous Nephropathy.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
2 still active
All registered trials
12
Any phase or sponsor naming "MIL62"
First trial start
2022
Feb 24, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MIL62", any sponsor or status.
Conditions studied
As listed on its trial records.
- Systemic Lupus Erythematosus
- Neuromyelitis Optica Spectrum Disorder
- Primary Membranous Nephropathy
Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "MIL62" as an intervention, largest first.
- A Phase 3 Clinical Study of MIL62 in Systemic Lupus ErythematosusPivotal-lookingRecruiting
Beijing Mabworks Biotech Co., Ltd.Industry
NCT07405970 · 316 participants (planned) · Start Apr 10, 2026 · Primary completion Dec 2028
Drug: MIL62; Placebo · For: Systemic Lupus Erythematosus
Sites: Beijing, China
- MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular LymphomaPivotal-lookingStatus unknown
Beijing Mabworks Biotech Co., Ltd.Industry
NCT04834024 · 168 participants (planned) · Start Jun 2, 2021 · Primary completion Mar 2025
Drug: Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide; lenalinomide · For: Follicular Lymphoma and Marginal Zone Lymphoma
Sites: Beijing, China
- A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous NephropathyPivotal-lookingStatus unknown
Beijing Mabworks Biotech Co., Ltd.Industry
NCT05862233 · 150 participants (planned) · Start Jun 2, 2023 · Primary completion May 13, 2025
Drug: MIL62; Cyclosporine · For: Primary Membranous Nephropathy
Sites: Beijing, China
Beijing Mabworks Biotech Co., Ltd.Industry
NCT05806099 · 132 participants (planned) · Start Jun 28, 2023 · Primary completion Nov 2025
Drug: MBS303 · For: Non-Hodgkin's Lymphoma
Sites: Beijing, China
- A Phase 2 Clinical Study of MIL62 in Systemic Lupus ErythematosusPivotal-lookingCompleted
Beijing Mabworks Biotech Co., Ltd.Industry
NCT05796206 · 123 participants · Start May 26, 2023 · Primary completion Nov 21, 2024
Drug: MIL62; placebo · For: Systemic Lupus Erythematosus
Sites: Beijing, China
- A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)Pivotal-lookingActive, not recruiting
Beijing Mabworks Biotech Co., Ltd.Industry
NCT05314010 · 102 participants · Start Aug 18, 2022 · Primary completion Feb 21, 2025
Drug: MIL62 · For: Neuromyelitis Optica Spectrum Disorder
Sites: Beijing, China
Beijing Mabworks Biotech Co., Ltd.Industry
NCT05398653 · 94 participants · Start Feb 24, 2022 · Primary completion Mar 4, 2025
Drug: MIL62; Cyclosporine and 1 more · For: Primary Membranous Nephropathy
Sites: Beijing, China
- MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)Status unknown
Beijing Mabworks Biotech Co., Ltd.Industry
NCT04110301 · 53 participants (planned) · Start Nov 28, 2019 · Primary completion Jan 9, 2024
Drug: Recombinant Humanized Monoclonal Antibody MIL62 Injection; Lenalidomide · For: Follicular Lymphoma and Marginal Zone Lymphoma
Sites: Beijing, China
- A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell LymphomaStatus unknown
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT04304040 · 43 participants · Start Jul 28, 2020 · Primary completion Dec 30, 2025
Drug: Orelabrutinib; Recombinant humanized monoclonal antibody MIL62 injection · For: B-cell Lymphoma Recurrent; B-cell Lymphoma Refractory
Sites: Bengbu, China; Beijing, China; Baoding, China · 10 sites in all
- Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus NephritisActive, not recruiting
Beijing Mabworks Biotech Co., Ltd.Industry
NCT07044115 · 41 participants · Start Nov 26, 2021 · Primary completion Jan 16, 2025
Drug: Recombinant Humanized Monoclonal Antibody MIL62 Injection; placebo · For: Lupus Nephritis
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Impact of afucosylation strategy on antibody function: a comparative study of glycoengineered anti-CD20 antibodies Obinutuzumab and Obinutuzumab beta.
Shuang Q, Sun M, Lin G, et al. · MAbs 2026
- Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial.
Wu L, Gu L, Fan W, et al. · Nat Med 2026
- Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial.
Wu L, Wei M, Gao F, et al. · Neurol Ther 2026
- Efficacy and safety of MIL62, a novel glycoengineered type ࡱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trial.
Shi Y, Zhou K, Zhou H, et al. · EClinicalMedicine 2024
- [Fe2(C10O8H2)]: an antiferromagnetic 3D iron(II) carboxylate built from ferromagnetic edge-sharing octahedral chains (MIL-62).
Sanselme M, Grenèche JM, Riou-Cavellec M, et al. · Chem Commun (Camb) 2002
Also in development for Systemic Lupus Erythematosus
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- CM313Phase 36 trials
Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness
- EnpatoranM5049, M5049 dosePhase 35 trials
EMD Serono Research & Development Institute, Inc. · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus
- ObexelimabPhase 34 trials
Zenas BioPharma (USA), LLC · Systemic Lupus Erythematosus, Warm Autoimmune Hemolytic Anemia, Relapsing Multiple Sclerosis
- Rese-celCABA-201Phase 34 trials
Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- AfimetoranBMS-986256, BLN-256Phase 32 trials
Beeline Medicines Corporation · Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.